Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated significant sales growth, with reported sales of $803 million in 2024, reflecting a 29% increase, and management anticipates continued growth, projecting revenues of $940-955 million for the upcoming period. Within the neuromodulation segment, there are optimistic projections regarding the aura6000 device, with estimates of market share expanding from 9.0% in 2027 to 14.9% by 2029, potentially leading to sales of $280 million. The company's diversified revenue streams—approximately 50% from the US, 21% from Europe, and the rest from global markets—enhance its financial stability and growth prospects within the specialized medical device sector.

Bears say

LivaNova is facing potential revenue growth that may stagnate in the low-single digits due to persistent challenges in its Neuromodulation and Cardiovascular sectors, accompanied by operating margin contraction and earnings that are likely to fall below market expectations. Risks also loom regarding the potential failure to secure FDA approval for critical products such as the aura6000, which could exacerbate slower growth trends in both the Neuromodulation and Cardiopulmonary segments. Consequently, these factors collectively contribute to a bearish outlook for the company's financial performance and future prospects.

Livanova (LIVN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 7 analysts, Livanova (LIVN) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.